Skip to main content
. 2024 Oct 11;34(10):1308–1313. doi: 10.1089/thy.2024.0224

FIG. 2.

FIG. 2.

(A). Expression levels of IGF1R mRNA in nonneoplastic thyroids (NT, n = 5) and tumor positive for IGF1R fusion (77T). (B). Expression levels of IGF1R for exons 1–13 and exons 14–21 revealed imbalanced expression of the 5′ and 3′ regions of the gene in tumor positive for the fusion. (C) qRT-PCR analysis of IGF1R mRNA levels upstream (exons 10–11) and downstream (exons 17–18) the fusion breakpoint for TG-IGF1R + tumor and matched nonneoplastic thyroid. Tumor shows increased expression of the 3′ region (exons 17–18) of IGF1R but not the 5′ region (exons 10–11). Matched normal shows low expression of IGF1R for both regions, 5′ and 3′. (D). FFPM values for TG-IGF1R (NM000875.5), TG-IGF1R (NM001291858.2), and IGF1R-TG shows predominant expression of TG-IGF1R fusion over IGF1R-TG. (E). Immunostaining of papillary thyroid cancer positive for TG–IGF1R showing strong cytoplasmic immunoreactivity with anti-IGF1R antibody (phospho-Y1161) in the tumor and lack of staining of adjacent normal thyroid tissue (Magnification: x100; Scale bar = 200 μm). (F). Heatmap displaying increased expression of selected genes related to MAPK output in 5 nonneoplastic thyroid tissues vs. tumor positive for IGF1R fusion. Red: upregulated genes; Blue: downregulated genes. (G). qRT-PCR analysis of NIS mRNA levels for tumor harboring the IGF1R fusion (77T) and matched normal (77N). NT: nonneoplastic tissue; FFPM: Fusion fragments per million total RNA-seq fragments.